How Biotech Startups Are Using Quantum Computing for Drug Discovery

In this episode of Biotech Business, Lucas and Luna explore how biotech startups are beginning to leverage quantum computing to accelerate drug discovery. They discuss the specific problem quantum computers are good at — simulating molecular interactions that classical computers struggle with — and highlight real companies like Menten AI and ProteinQure that are already running quantum chemistry calculations. The hosts explain the difference between noisy intermediate-scale quantum (NISQ) devices and fault-tolerant quantum computers, and why today's hybrid classical-quantum algorithms matter for drug developers in 2026. They also touch on the race between pharma giants like Roche and JPMorgan's quantum investments, and the funding landscape for quantum-native biotech. A concrete look at a cutting-edge intersection of physics, biology, and computing. #QuantumComputing #DrugDiscovery #BiotechStartups #MentenAI #ProteinQure #NISQ #QuantumChemistry #MolecularSimulation #PharmaInnovation #Roche #JPMorgan #HybridAlgorithms #ComputationalBiology #BusinessAndTechnology #FexingoBusiness #StartupFunding #DrugDevelopment #BiotechBusiness Keep every episode free: buymeacoffee.com/fexingo